Check out your Company Bowl for anonymous work chats.
Agios is proud to share our Q2 2023 Business Highlights and Financial Results!
We've closed our deal and are excited for the next chapter of our story!
Agios Announces Closing of Oncology Business Sale to Servier | Agios Pharmaceuticals, Inc.
We're re-imagining the other side of possible with a singular focus on genetically defined diseases -- and the right home and resources for our oncology portfolio.
Agios to Focus on Developing and Commercializing Innovative Treatments for Genetically Defined Diseases and Sell Its Oncology Business to Servier for Up to $2 Billion Plus Royalties | Agios Pharmaceuticals, Inc.
We are excited to share about our partnership with Werk, and how we are thinking about flexibility as an organization! http://glassdoor.com/slink.htm?key=vMCma
Case Study: How Agios Pharmaceuticals Leveraged New Data on Flexibility to Customize the Employee Experience | Werk
We recently shared our Chief Executive Officer succession plan - click here to learn more!
Agios Announces Chief Executive Officer Succession Plan | Agios Pharmaceuticals, Inc.
Excellent Forbes piece on fighting cancer one patient at a time with precision medicines. At Agios, this is what motivates, inspires and drives us. http://glassdoor.com/slink.htm?key=vQDPI
Fighting Cancer One Patient at a Time
Celgene and Agios received approval by the FDA for a new therapy for IDH2m relapsed/refractory acute myeloid leukemia http://glassdoor.com/slink.htm?key=vQ4K9
FDA Grants Approval of IDHIFA®, the First Oral Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH2 Mutation
Business Insider reports on our approach to tackling diseases through dysregulated metabolism. Check it out: http://glassdoor.com/slink.htm?key=vQFx5
A small Boston biotech is at the heart of a groundbreaking approach to tackling cancer
http://glassdoor.com/slink.htm?key=vQC82
Agios Appoints Ian Clark to Board of Directors
http://glassdoor.com/slink.htm?key=vQaki
Courage in Clinical Trials